Ivermectin is a macrocyclic lactone that acts as a positive allosteric modulator of were observed on M253L, S276V and S222M, respectively. Antagonism by ivermectin was non-surmountable and had no effect on EC 50 of acetylcholine, indicating that it is acting non-competitively. The seven mutations that influence allosteric modulation by ivermectin are located close to a predicted intra-subunit transmembrane cavity. Computer docking simulations provide support for the hypothesis that ivermectin binds in close proximity to this cavity. We conclude that transmembrane mutations in α 7 nAChRs are able to convert ivermectin from a positive to a negative allosteric modulator.
Introduction
Ivermectin is a large macrocyclic lactone (Fig. 1A) . It is a synthetic derivative of a naturally-occurring compound, isolated by fermentation of Streptomyces avermitilis and is used commercially as an antiparasitic agent in both human and veterinary medicine (Burkhart, 2000) . The antiparasitic activity of ivermectin is thought to be due to its action as an agonist of invertebrate glutamate-gated chloride channels (Raymond and Sattelle, 2002; Arena et al., 2004) . In addition, ivermectin has been shown to modulate several other ligand-gated ion channels. For example, it is an agonist of invertebrate histamine-gated chloride channels (Zheng et al., 2002) receptors (Sigel and Baur, 1987; Krůšek and Zemková, 1994) , glycine receptors (Shan et al., 2001 ) and ATP (P2X) receptors (Khakh et al., 1999) . Ivermectin has also been reported to act as an agonist of GABA A and glycine receptors (Sigel and Baur, 1987; Adelsberger et al., 2000; Shan et al., 2001 ).
There has been considerable interest in positive allosteric modulators of α 7 nAChRs (for recent reviews see Bertrand and Gopalakrishnan, 2007; Moaddel et al., 2007) . In part, this interest has been simulated by suggestions that such compounds may have therapeutic potential as cognitive enhancers in connection with disorders such as Alzheimer's disease and schizophrenia (Hurst et al., 2005; Bertrand and Gopalakrishnan, 2007; Moaddel et al., 2007) . A wide variety of compounds in addition to ivermectin have been reported to act as positive allosteric modulators of α 7 nAChRs. These include proteins such as serum albumins (Conroy et al., 2003) This article has not been copyedited and formatted. The final version may differ from this version. (Timmermann et al., 2007) and 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methyl-isoxazol-3-yl)-urea (PNU-120596) (Hurst et al., 2005) . All of these compounds potentiate peak agonist-induced responses, but have been classified as being either 'type I' or 'type II' positive allosteric modulators, based on their effect on receptor desensitization (Bertrand and Gopalakrishnan, 2007) . Type I compounds (such as ivermectin) have little or no effect on receptor desensitization, whereas type II compounds (such as PNU-120596) reduce levels of desensitization seen during prolonged agonist exposure (Krause et al., 1998; Hurst et al., 2005) .
For some of these allosteric potentiators (for example galanthamine), the location of the binding site has been proposed to be on the nAChR extracellular domain (Hansen and Taylor, 2007) . In contrast, for allosteric potentiators such as LY-2087101 and PNU-120596, a transmembrane binding site has been proposed (Young et al., 2008) . Recently, it has been suggested, on the strength of computer docking simulations, that ivermectin may also interact with nAChRs via a transmembrane binding site (Sattelle et al., 2009) . In the present study we have examined the ability of ivermectin to act as an allosteric modulator on a series of mutated and chimeric α 7 nAChR subunits. We conclude that the nAChR transmembrane domains play a critical role in influencing allosteric modulation by
ivermectin. In addition, we have demonstrated that single point mutations located
This article has not been copyedited and formatted. The final version may differ from this version. (Cooper and Millar, 1998; Gee et al., 2007) , as has a plasmid expression construct (pcDNA3-hRIC-3) containing the human RIC-3 cDNA (Lansdell et al., 2005) . Construction of α 7 nAChRs containing site-directed mutations has also been described previously (Young et al., 2008) .
Xenopus oocyte electrophysiology. Xenopus laevis oocytes were isolated and defolliculated as described previously (Young et al., 2007) . Heterologous expression was achieved by injection of plasmid cDNA constructs (10-30 ng) into oocyte nuclei.
In the case of the α 7 cDNA containing the A225D mutation (Young et al., 2008) , expression of functional receptors was inefficient. For this reason, the A225 mutation was co-expressed with the molecular chaperone RIC-3, which has been found previously to enhance nAChR maturation (Lansdell et al., 2005; Millar, 2008 et al., 2008) . To avoid bias, a 'blind docking' approach was used in which no assumptions were made concerning where within the transmembrane region ivermectin might be expected to bind. Flexibility of rotatable bonds in ivermectin was permitted during the docking simulation. Predicted Gibbs free energy of binding (ΔG)
was calculated as described (Morris et al., 1998) , as was the predicted equilibrium constant for binding (K eq ), using the equation K eq = e -ΔG/RT (where R = gas constant,
T = absolute temperature).
This article has not been copyedited and formatted. The final version may differ from this version. was co-applied with acetylcholine (in the absence of pre-application). Strong potentiation was, however, observed when ivermectin was pre-applied (for 60 seconds) in addition to it being co-applied with acetylcholine ( Fig. 1B and 1C ).
Consequently, this application protocol (a combination of pre-and co-application of ivermectin) was used for all experiments described in the present study. These findings, conducted with rat Table   2 ). Three mutations (S222M, M253L and S276V, located in TM1, TM2 and TM3, respectively) had a particularly dramatic and somewhat unexpected effect. All of these mutations caused ivermectin to act as an inhibitor, rather than as a potentiator.
Ivermectin caused agonist-evoked responses to be inhibited by 89.1±6.6% (n=4) in S222M, 55.6±8.8% (n=3) in M253L and 84.2±3.5% (n=4) in S276V ( Fig. 3 and Table   2 ).
Of the three mutations that caused ivermectin to act as an inhibitor, one ( 13 ivermectin were in closest proximity to S276V, a mutation that had no significant effect on the type II allosteric modulator PNU-120596 (Young et al., 2008) . PNU-120596 is a much smaller molecule than ivermectin and is predicted to bind at a lower position within the intrasubunit cavity (Young et al., 2008) .
This article has not been copyedited and formatted. The final version may differ from this version. , 2007; Jelínkova et al., 2008) . This may, therefore, be a common mechanism by which ivermectin is able to modulate a variety of diverse ion channels.
The finding that ivermectin acts as an inhibitor of is situated close to the bottom of the cavity. Four of the mutations that we have identified in the present study as influencing allosteric modulation by ivermectin (S222M, A225D, M253L and C459Y) also reduce potentiation by PNU-120596. In contrast, three mutations (Q272V, S276V and T456V) have a significant effect on ivermectin but have no effect on PNU-120596. The side chain of S276 is predicted to point towards the interior of the cavity (as are all of those found to influence PNU-120596) but it is located much closer to the top of the transmembrane cavity than are the mutations that effect PNU-120596 (Fig. 5) . In contrast to all of the above mutations, the side chains of Q272 and T456V are not predicted point towards the centre of the cavity (Fig. 5) . Whereas the predicted binding site for PNU-120596 is in very close proximity to all amino acids that, when mutated, exert a significant effect on potentiation (Young et al., 2008) , this is not the case for ivermectin. The two lowest energy docked positions of ivermectin lie in closest proximity to Q272 which, interestingly, is one of the three amino acids which, when mutated, affect ivermectin but have no significant effect on potentiation by PNU-120596 (Fig. 5) . It is tempting to speculate that the positive and negative modulatory activity of ivermectin might be a consequence of its ability to interact with the receptor in different orientations but we do not wish to over-interpret these computer-docking studies, particularly since they are conducted with a homology model (based on the Torpedo nAChR). Nevertheless, these docking studies provides support for the possibility that ivermectin binds in the This article has not been copyedited and formatted. The final version may differ from this version. Table   2 . Data are means ± SEM (n=3-8). Side chains of amino acids which, when mutated, had a significant effect on potentiation by ivermectin are indicated by colored spheres. Different colors have been used to indicate differing effects of mutations on allosteric modulation by ivermectin (this study) and PNU-120596 (Young et al., 2008) . A225D (TM1) and C459Y (TM4), which caused reduced potentiation of both ivermectin and PNU-120596 are shown in blue. Q272V (TM3) and T456V (TM4), which caused reduced potentiation of ivermectin but had no effect on PNU-120596 are shown in purple.
S222M (TM1) and M253L (TM2), which caused ivermectin to act as an inhibitor and caused reduced potentiation by PNU-120596 are shown in red. S276V (TM3), which caused ivermectin to act as an inhibitor but had no effect on PNU-120596 is shown in orange.
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